Research programme: peptide conjugate therapeutics - Esperance

Drug Profile

Research programme: peptide conjugate therapeutics - Esperance

Alternative Names: EP 200; EP 300; EP-302

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Esperance Pharmaceuticals
  • Class Antineoplastics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 May 2017 Preclinical development is ongoing in Cancer in USA (Esperance pipeline, May 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
  • 20 Apr 2010 Pharmacodynamics data from preclinical studies in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top